Berjame, Angelita R.

HRN: 17-64-79  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/25/2023
CEFTAZIDIME 1GM (VIAL)
09/25/2023
10/01/2023
IV
1g
Q8
Infected Wound
Waiting Final Action 

Indication:  Empiric    Type of Infection:  BloodstreamSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: